Tumor Mutations and VTE Risk – New Insights from a 12,500-Patient Cancer Study – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Naomi Cornish et al, adding:
”Associations of Tumor Somatic Mutations with Cancer-Associated Venous Thromboembolism
Analysis of 12,507 cancer patients reveals that somatic mutations in CDKN2A, KRAS, PCDH15, and TP53 significantly increase VTE risk, while high tumor mutational burden is protective, offering novel insights into cancer-associated thrombosis pathophysiology and future risk prediction tools.”
Title: Associations of tumor somatic mutations with cancer-associated venous thromboembolism
Authors: Naomi Cornish, Rebecca Ward, Matthew T. Warkentin, Chrissie Thirlwell, Andrew D. Mumford, Sarah K. Westbury, Philip C. Haycock
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
May 22, 2026, 17:30Veronica Sanchez: Do You Live with Pain after a Stroke?
-
May 22, 2026, 17:25Maxime Dely: A Simple but Powerful Indicator of Platelet Quality
-
May 22, 2026, 17:24Jim Hoffman: A New Approach to Balancing Host Defense and Tissue Protection
-
May 22, 2026, 17:22Lucia Rugeri: Advancing Multidisciplinary Care for Heavy Menstrual Bleeding in Women with Bleeding Disorders
-
May 22, 2026, 17:20Nour Al-Mozain: Optimizing PBSC Collection Through Real-Time CD34+ Monitoring
-
May 22, 2026, 16:30Buse Bor: New Publication on Therapeutic Interventions for Women with Obstetric APS
-
May 22, 2026, 16:29Danny Hsu: The Reversal Dilemma – Rethinking our approach to DOAC-associated ICH
-
May 22, 2026, 16:28Bartosz Hudzik: High Bleeding Risk Does Not Always Mean Bleeding-Risk Predominance
-
May 22, 2026, 16:26Sandeep De: Omicron COVID Infections Linked to Coronary Thrombosis without Detectable Plaque